Nivolumab Market Report 2026

The nivolumab market size has grown rapidly in recent years. It will grow from $1.92 billion in 2025 to $2.17 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to rising prevalence of melanoma and nsclc, early approvals of nivolumab for metastatic cancers, increasing hospital infrastructure for oncology treatment, growth in oncology research and clinical trials, adoption of monoclonal antibody therapies.

The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $3.63 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to expansion of nivolumab indications, rising geriatric cancer population, integration with combination therapies, increasing investment in biologics manufacturing, growth in emerging markets oncology infrastructure. Major trends in the forecast period include immuno-oncology advancements, combination therapy development, personalized cancer treatment, expansion of hospital-based oncology services, increasing adoption of targeted therapies.

The rising incidence of non-small cell lung cancer (NSCLC) is expected to drive the growth of the Nivolumab market in the coming years. Non-small cell lung cancer (NSCLC) is a type of lung cancer that originates in the epithelial cells of the lungs. Nivolumab is an approved therapy used to treat patients with advanced NSCLC due to its effectiveness in managing this type of cancer. For instance, in March 2023, the American Society of Clinical Oncology, a US-based professional society representing oncologists across subspecialties, reported that an estimated 238,340 people (117,550 men and 120,790 women) will be diagnosed with lung cancer in the United States, with NSCLC accounting for 81% of all cases. Therefore, the rising incidence of non-small cell lung cancer (NSCLC) is driving growth in the Nivolumab market.

The increasing adoption of personalized medicine is expected to propel the growth of the Nivolumab market going forward. Personalized medicine is a medical approach that customizes treatment and prevention strategies according to an individual’s genetic profile, lifestyle, and environment rather than following a one-size-fits-all model. Advances in genetic testing have accelerated the use of personalized medicine, allowing treatments to be tailored to each patient. Nivolumab is applied in personalized medicine by targeting specific immune pathways based on a patient’s tumor characteristics, enabling more precise and effective cancer treatment. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a substantial increase from six approvals in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the Nivolumab market.

Major companies operating in the Nivolumab market are focusing on developing new formulations and expanding treatment indications to improve patient convenience and strengthen their immuno-oncology portfolios. For instance, in December 2024, the FDA, a US-based federal agency, approved Opdivo Qvantig, a subcutaneous formulation of Nivolumab combined with hyaluronidase-nvhy, for use across all previously approved adult solid-tumor indications of intravenous Nivolumab. This new option allows monotherapy, maintenance therapy after Opdivo plus Yervoy, or combination treatment with chemotherapy or cabozantinib. The approval was supported by the Phase 3 CHECKMATE-67T trial, which showed comparable drug exposure, similar safety, and a slightly higher response rate than IV Nivolumab in patients with advanced renal cell carcinoma. With flexible dosing schedules and maintained efficacy, the subcutaneous formulation offers a more convenient alternative for patients and strengthens Bristol Myers Squibb’s immuno-oncology portfolio.

Major companies operating in the nivolumab market are Bristol-Myers Squibb Company, Ono Pharmaceutical Co. Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc., Dr. Reddy’s Laboratories Ltd., Biocon Limited, Samsung Bioepis Co. Ltd., Celltrion Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Intas Pharmaceuticals Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Zydus Lifesciences Limited, mAbxience, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., WuXi Biologics, Lonza Group AG, Samsung Biologics.

North America was the largest region in the nivolumab market in 2025. The regions covered in the nivolumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nivolumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created both challenges and opportunities for the nivolumab market by affecting the cost and availability of biologics, raw materials, and active pharmaceutical ingredients used in monoclonal antibody production. The resulting increase in production costs has impacted adoption in hospital and clinic segments, particularly in regions such as Asia-Pacific and Europe where manufacturing and supply chains are concentrated. To mitigate these impacts, companies are exploring local sourcing, diversifying suppliers, and optimizing manufacturing processes. In some cases, tariffs have encouraged domestic production, potentially reducing long-term dependency on imports.

The nivolumab market research report is one of a series of new reports that provides nivolumab market statistics, including nivolumab industry global market size, regional shares, competitors with a nivolumab market share, detailed nivolumab market segments, market trends and opportunities, and any further data you may need to thrive in the nivolumab industry. This nivolumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nivolumab is a fully human immunoglobulin G4 (IgG4) antibody that targets programmed cell death protein 1 (PD-1) and is approved at a dose of 3 mg/kg for metastatic or unresectable melanoma, metastatic non-small cell lung cancer following platinum-based chemotherapy, and metastatic renal cell carcinoma in the second-line setting. It is a targeted therapy used to treat and manage various cancers by enhancing the immune system.

The main types of nivolumab are injection 4 mL and injection 10 mL. Nivolumab 40 mg/4 mL (10 mg/mL) solution is provided in a single-use vial. This formulation is used for the treatment of melanoma, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma. It is administered via intravenous and other routes for indications including melanoma, NSCLC, malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and others. It is used in clinics, hospitals, and other healthcare settings.

The nivolumab market consists of sales of opdivo, nivolumab injection, generic Nivolumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.